Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study
Lipid metabolism derangement contributes to increased cardiovascular risk in Rheumatoid Arthritis (RA). It is still debated whether and how tocilizumab, an interleukin-6 receptor inhibitor used in active RA, impacts cardiovascular risk. We studied the effect of tocilizumab on the regulation of macro...
Main Authors: | Daniela Greco, Roberta Gualtierotti, Pasquale Agosti, Maria Pia Adorni, Francesca Ingegnoli, Matteo Rota, Franco Bernini, Pier Luigi Meroni, Nicoletta Ronda |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/7/2157 |
Similar Items
-
RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
by: E Yu Panasyuk, et al.
Published: (2011-08-01) -
Tocilizumab in the Treatment of Juvenile Rheumatoid Arthritis
by: V.V. Berejniy, et al.
Published: (2015-03-01) -
Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
by: Han Joo Baek, et al.
Published: (2019-07-01) -
PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01) -
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series
by: Rossella Talotta, et al.
Published: (2018-06-01)